federal_register: 2021-27351
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-27351 | Inspection of Injectable Products for Visible Particulates; Draft Guidance for Industry; Availability | Notice | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Inspection of Injectable Products for Visible Particulates." Visible particulates in injectable products can jeopardize patient safety. This draft guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development, manufacturing controls, visual inspection techniques, particulate identification, investigation, and corrective actions designed to assess, correct, and prevent the risk of visible particulate contamination. The draft guidance also clarifies that meeting an applicable U.S. Pharmacopeia (USP) compendial standard alone is not generally sufficient for meeting the current good manufacturing practice (CGMP) requirements for the manufacture of injectable products. | 2021-12-17 | 2021 | 12 | https://www.federalregister.gov/documents/2021/12/17/2021-27351/inspection-of-injectable-products-for-visible-particulates-draft-guidance-for-industry-availability | https://www.govinfo.gov/content/pkg/FR-2021-12-17/pdf/2021-27351.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Inspection of Injectable Products for Visible Particulates." Visible particulates in injectable products can jeopardize patient... |